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RESEARCH

Cost and Utilization of Behavioral Health Medications Associated
with Rescission of an Exemption for Prior Authorization for Severe
and Persistent Mental Illness in the Vermont Medicaid Program
Jason C. Simeone, PhD; Rita M. Marcoux, MBA, RPh; and Brian J. Quilliam, PhD, RPh

ABSTRACT
BACKGROUND: In recent years, many state Medicaid programs have
implemented preferred drug lists (PDL) to control pharmaceutical costs
by generating supplemental rebate revenues and directing providers to
the most cost-effective treatments. Two states, Michigan and Vermont,
sought approval from the Centers for Medicare & Medicaid Services for
supplemental rebates for their Medicaid fee-for-service programs in 2002.
Behavioral health medications were largely excluded from PDLs and other
managed care initiatives implemented by state Medicaid programs because
of significant opposition to any impact on this “vulnerable” population. In
November 2001, the Vermont Medicaid program implemented the Vermont
Health Access Pharmacy Benefit Management Program, a PDL designed to
promote cost-effective use of medications. Despite the potential cost savings resulting from implementation of a PDL, behavioral health providers
and advocates in the state of Vermont opposed the implementation of the
managed care initiative for beneficiaries with severe mental illness, and
after January of 2002, Vermont’s program was changed to exempt beneficiaries meeting the “severe and persistent mental illness” (SPMI) criteria
from prior authorization (PA) for behavioral health medications not on the
Medicaid PDL. The SPMI exemption was phased out by June 30, 2006.
OBJECTIVES: To determine the effects of the rescission of the PA exemption on utilization and costs of 3 classes of behavioral health medications
(antidepressants, antipsychotics, and anxiolytics/sedatives). Secondary
analyses were conducted to assess the association between rescission of
the PA exemption and 2 quality measures that might be associated with
pharmacy management policy: (a) behavioral health hospitalizations and
(b) high-dose prescribing of antipsychotics, defined as dosing that exceeded the manufacturer-recommended maximum dose by 25%.
METHODS: This was a retrospective analysis of pharmacy claims for
beneficiaries of the Office of Vermont Health Access Medicaid Program
for dates of service from July 1, 2005, through December 31, 2007. The
12-month PA exemption period for 3 categories of drugs (antidepressants,
antipsychotics, and anxiolytics/sedatives) was July 1, 2005, through June
30, 2006; and the post-PA exemption period was the 12 months from
January 1, 2007, through December 31, 2007, following rescission of the
SPMI exemption. Costs in this analysis were defined as the amount paid
by Medicaid, excluding federal drug rebates paid by drug manufacturers
and supplemental rebates associated with the PDL program. Costs were
adjusted for inflation using the Consumer Price Index for medical costs.
Frequencies were used to identify trends between medication classes and
time periods. Medical claims from the 2 time periods were used to assess
inpatient hospitalization trends. Descriptive statistics, Pearson chi-square
tests (for categorical data), and t-tests (for continuous data) were used to
assess the 2 study cohorts.
RESULTS: 17.8% (n=22,130) of 124,169 eligible beneficiaries in the PA
exemption period had 1 or more pharmacy claims in the 3 classes of
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medications exempt from PA versus 19.2% (n=23,717) of 123,499 eligible
beneficiaries in the post-PA exemption period. Utilization of behavioral
medications per member per month (PMPM) increased by 14.3% from
0.14 claims PMPM in the PA exemption period to 0.16 claims PMPM in the
post-PA exemption period, similar to the 14.1% increase in the utilization
of nonbehavioral medications (from 0.64 to 0.73 claims PMPM). Utilization
changed little between the PA exemption period and the post-PA exemption period for the 3 individual classes of behavioral health drugs, 0.08
claims PMPM versus 0.09 claims PMPM for antidepressants and 0.03 for
both study periods for both antipsychotics and anxiolytics/sedative hypnotics. PMPM costs for the 3 drug classes exempt from PA increased by
2.1% from $12.76 to $13.03, compared with a 12.2% increase from $42.58
PMPM to $47.79 PMPM for nonbehavioral health medications. The small
2.1% increase in PMPM costs for the 3 formerly PA-exempt drug classes
was attributable in part to a 12.9% reduction in average cost per pharmacy
claim, from $94.05 to $81.92, including a 24.8% reduction in the average
cost per antidepressant claim, from $65.59 to $49.33. For the subgroup
of beneficiaries taking atypical antipsychotic medications, the percentage
with high-dose prescriptions decreased from 3.1% to 2.2%. Mental health
inpatient hospitalizations also decreased from 0.6% of beneficiaries in the
PA exemption period to 0.4% in the post-PA exemption period.
CONCLUSIONS: In a Medicaid population excluding Medicare dual-eligible
beneficiaries, the rescission of a PA exemption for 3 major classes of
behavioral health medications in a PDL was not associated with decreased
utilization of formerly PA-exempt behavioral health medications. The
increase in PMPM spending for the formerly PA-exempt behavioral health
medications was small compared with the increase in PMPM cost for nonbehavioral health medications, and there were fewer beneficiaries with
hospitalization for mental health reasons in the period after rescission of
the PA exemption.
J Manag Care Pharm. 2010;16(5):317-28
Copyright © 2010, Academy of Managed Care Pharmacy. All rights reserved.

What is already known about this subject
• Most states implemented Medicaid cost containment measures
between 2001 and 2005 to control rising pharmaceutical costs;
by 2009, 46 states had implemented a prior authorization (PA)
program, and 45 states had implemented a preferred drug list
(PDL).
• Medicaid currently pays for greater than 50% of all publicly
funded behavioral health care and greater than 25% of all behavioral health care nationwide. Previous studies have shown that
managed care initiatives reduce expenditures but can have variable effects on health care utilization.
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What this study adds
• After rescission of a PA exemption and implementation of a
behavioral health PA requirement in the Vermont Medicaid program, per member per month pharmaceutical costs for behavioral
health medications increased by 2.1% compared with a 12.2%
increase for all nonbehavioral health medications, and utilization
of the formerly PA-exempt behavioral health medications did not
decrease.
• Preliminary results indicate that implementation of a PDL and
corresponding PA program for a mental health subgroup of the
Medicaid population were not associated with an increase in
inpatient mental health hospitalizations, and use of high-dose
antipsychotics (meeting the threshold for PA) decreased from
3.1% to 2.2% of beneficiaries.

I

mplementation of the Medicare Part D drug benefit on
January 1, 2006, shifted about one-half of Medicaid spending
(for dual-eligible beneficiaries) to the Medicare program, but
states continued to seek control of rising pharmaceutical costs
using tools such as preferred drug lists (PDLs), prior authorization (PA), and supplemental rebate programs that were initiated
between 2001 and 2005.1 By 2009, 45 state Medicaid programs
had a PDL, and 46 states had PA requirements for pharmaceuticals. Increases in Medicaid spending per beneficiary
declined from 14.0% in 2000-2002 to 0.7% in 2005-2007, after
adjustment for the shift of costs to Medicare for dual-eligible
beneficiaries.2 Prescription drug trends are driven by a number of factors including price increases, utilization, mix, the
introduction of new products, pharmaceutical advertising, and
the increasing number of biotechnology products used to treat
chronic conditions.3 Fiscal constraints are requiring Medicaid
officials to seek innovative approaches to delivering quality
health care to an increasing number of individuals requiring
care for complex and chronic health conditions.
According to the Centers for Medicare & Medicaid Services
(CMS), 33.4 million beneficiaries or approximately 71% of the
national Medicaid population were enrolled in a managed care
program by 2008.4 Every state except Alaska and Wyoming
has all, or a portion, of its Medicaid population enrolled in
some form of managed care.1 Managed Medicaid organizations
generate rebates that do not benefit from the best price mandates of the Omnibus Budget Reconciliation Act (OBRA) rebate
program administered by CMS. While states do share in OBRA
rebates with the federal government, a few states challenged
CMS to allow them to work with pharmaceutical manufacturers to increase their rebate revenue by entering into supplemental rebate agreements based on the implementation of PDLs in
their states.1,5 Manufacturers agreed to pay additional rebates
for preferred placement on the Medicaid PDLs. Although
318 Journal of Managed Care Pharmacy
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physicians are permitted to prescribe all medications, “preferred” medications do not require PA when the pharmacy
claim is submitted.
In the late 1990’s, behavioral health medications were
largely excluded from PDLs and managed care initiatives
implemented by state Medicaid fee-for-service programs out
of concern for the “vulnerability” of the beneficiaries taking
these medications.6 This exclusion from managed care and
care management initiatives occurred at a time when spending
on behavioral health medications represented approximately
20% of all Medicaid drug expenditures.7 Increased utilization
is likely a result of several factors; newer medications may
have fewer side effects, and there has been a decrease in the
stigmatization of individuals taking behavioral medications.
In addition, antidepressants, antipsychotics, and anxiolytics
are increasingly being prescribed for off-label uses.8 American
pharmaceutical manufacturers are developing at least 300 new
medications designed to treat the nearly 60 million Americans
suffering from behavioral disorders.9 Although the development of so many new medications to treat behavioral disorders
is promising, states must still ensure that behavioral health
programs are meeting the needs of their beneficiaries in a fiscally responsible manner.
The State of Vermont’s Medicaid program is managed by
the Office of Vermont Health Access (OVHA), and OVHA
programs cover approximately 175,000 beneficiaries. In early
2000, government officials in Vermont were under constant
pressure to control increasing drug expenditures without
reducing services.10 In 2002, the General Assembly adopted
legislation authorizing a prescription drug cost containment
program that included the implementation of a PDL and a PA
program for nonpreferred drugs.11-12 A number of constituent
groups in the mental health advocacy community, including
caregivers and physicians, supported an exemption from PA
for behavioral health medications in the PDL.13 In response to
their concerns, the Vermont legislature exempted beneficiaries identified as having “severe and persistent mental illness”
(SPMI) from PA for any medication being used to treat their
behavioral health illness regardless of the positioning of the
medication on the PDL.14 The SPMI designation was defined in
2002 by the following criteria:14
• Patient diagnosed with schizophrenia or bipolar disorder.
• Patient diagnosed with an International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
diagnosis code for mental health or substance abuse (including major depression, 290.00 - 319.00) and has or has had a
history of impairment due to the mental illness that affects
his/her ability to function such that the patient is suicidal,
has no friends, neglects family, is unable to work or keep
a job, is withdrawn to home or room, stays in bed all day,
becomes violent, or has even lesser degrees of functioning
(Global Assessment of Functioning Scale score of 50 or less).
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• Patient is a past or current user of traditional or atypical
antipsychotic medication.
• Patient has received chronic therapy with any antidepressant medication (received at least 300 days supply of medication during a 365 day period).
• Patient has received chronic therapy with any central nervous system stimulant medication (received at least 240
days supply of medication during a 365 day period).
• Presence of a Community Rehabilitation and Treatment
(CRT) code in eligibility file.
• Patient less than 18 years of age.
SPMI exemption was determined on each pharmacy claim;
therefore an overall marker of the SPMI exemption was not
a part of a beneficiary’s eligibility file, and exemption was
determined each time the beneficiary presented a new prescription for a behavioral health medication. Furthermore,
the policy stipulated that a beneficiary found to be exempt
for any reason other than age would remain exempt as long
as he or she continued to meet at least 1 of the SPMI exemption criteria.14 This inclusive exemption policy gave prescribers continued flexibility in managing the care of these SPMI
beneficiaries while allowing the OVHA the ability to implement the new PDL and PA policy to ensure fiscal and clinical
responsibility of the overall program. A new initiative was
added as part of the PA policy that monitored the use of highdose prescribing of behavioral health medications to ensure
that patients did not continue to receive high-dose therapy
that offered limited or no clinical benefit. The program and
its PDL were authorized by the state legislature in 2002 for
implementation in the state fiscal year ending June 30, 2002.14
Both current and historical OVHA PDLs are available online
on the OVHA website (http://ovha.vermont.gov/for-providers/
preferred-drug-list-clinical-criteria). The SPMI exemption to
the PDL and PA program was scheduled to end July 1, 2004,
but was extended through June 30, 2006. In response to
concerns from the health care community and caregivers, the
OVHA permitted beneficiaries using nonpreferred medications
prior to the exemption rescission to be “grandfathered” to
prevent “destabilization” of therapy. However, lapses in drug
therapy of 4 months or longer resulted in the application of the
PDL for these beneficiaries.14
The utilization and cost of these behavioral health medications continued to escalate and remained in the top therapeutic classes by expenditure in the state Medicaid program
through 2005. The 2006 Budget Act passed by the Vermont
legislature had provisions to allow the inclusion of behavioral
health drugs on the PDL.14 In 2006, the OVHA revised its PDL
and PA program to include the previously exempt behavioral
health classes of medications, and SPMI patients were then
subject to the PDL program requirements.14 The phase-out of
the PA exemption was not implemented in a “hard edit” in the
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pharmacy claims processing system until June 2006 because
of the major changes that took place with eligibility associated
with implementation of the Medicare Part D benefit beginning
in January 2006.
We conducted a retrospective study of PA exemption
and post-PA exemption cohorts to assess the association of
Vermont’s implementation of a PDL and PA program for behavioral health medications with health care utilization and costs.
We evaluated (a) behavioral health medication utilization and
drug costs in 3 of the major drug classes, and (b) 2 measures
that might capture some of the possible adverse consequences
of drug use restrictions: use of high-dose antipsychotic agents
and mental health hospitalizations before and after the rescission of the SPMI exemption.
■■ Methods
We conducted a nonconcurrent retrospective cohort study,
evaluating 2 time periods in relation to OVHA’s rescission of
the SPMI exemption. The first time period for this analysis,
July 1, 2005 to June 30, 2006, represented the final 12-month
period during which beneficiaries who were designated as
SPMI were exempt from PDL and PA requirements for behavioral health medications, hereafter referred to as the PA exemption period. We identified a second 12-month period during
which the PDL and PA programs were fully implemented from
January 1, 2007 through December 31, 2007, as the post-PA
exemption period. Our selection of these time periods allowed
for a 6-month wash-out period after rescission of the SPMI
exemption. For each of these time periods, we included all
beneficiaries with continuous enrollment during the interval.
From these eligible populations, we then excluded: (a) persons
eligible for Medicare Part D including dual eligibles (because
Medicare became the primary payer for pharmaceuticals
beginning in January 2006, and the OVHA as secondary payer
did not apply the PDL and PA program to these claims); (b)
beneficiaries who qualified for pharmaceutical aid from state
programs other than Medicaid; and (c) beneficiaries being
treated for hemophilia and Hunter’s syndrome (because high
costs for associated pharmaceutical agents would skew the
cost analyses). After the exclusion of beneficiaries, 124,169
Medicaid beneficiaries qualified during the PA-exemption
period (Figure 1), and 123,449 beneficiaries qualified for inclusion in the post-PA exemption period (Figure 2).
Simple descriptive statistics were used to describe the characteristics of the populations in both study periods. Descriptive
statistics included means and standard deviations (for continuous covariates) and frequencies (for categorical variables
of interest). We compared the 2 time periods for differences in
demographic characteristics including age, gender, and race/
ethnicity using data collected by OVHA and contained in the
Vermont Medicaid eligibility files.
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FIGURE 1

Selection of Beneficiaries for PA Exemption Cohort

Vermont Medicaid beneficiaries enrolled from
July 1, 2005, through June 30, 2006
n = 182,653
Beneficiaries excluded for dual eligibility in
Medicaid and Medicare
n = 38,253 (20.9%)
Beneficiaries enrolled only in Medicaid
n = 144,400
Beneficiaries excluded for enrollment in other
OVHA programs
n = 20,228
Beneficiaries with claims paid only by Medicaid
n = 124,172
Beneficiaries excluded with hemophilia (n = 3)
Beneficiaries excluded with Hunter’s Syndrome (n = 0)
Eligible PA exemption cohort
n = 124,169
OVHA = Office of Vermont Health Access; PA = prior authorization.

Behavioral Medication Utilization and Cost Analyses
The next phase of these analyses entailed estimating the prevalence of behavioral medication use and the associated costs
to the Medicaid program. For our analyses, we focused on 3
distinct classes of medications that were included in the SPMI
exemption: antidepressants, antipsychotics, and anxiolytics/
sedative hypnotics. The OVHA uses the First DataBank (First
DataBank, San Francisco, CA) Specific Therapeutic Class (STC)
codes to identify drug classes. To identify medications of interest, we used STC codes to identify claims among eligible beneficiaries for antidepressants (e.g., duloxetine, sertraline, and
amitriptyline), antipsychotics (e.g., aripiprazole, haloperidol)
and anxiolytics/sedative hypnotics (i.e., anti-anxiety medications such as alprazolam; and barbiturate and nonbarbiturate
sedative-hypnotics such as zolpidem). After preliminary identification of pharmacy claims using these STC codes, we also
completed a text-string search to verify the medications listed
in each class identified during the preliminary classification.
We estimated utilization rates for overall behavioral health
medication at the beneficiary level where the denominator
included the total number of eligible beneficiaries within
each cohort and the numerator included the total number
of beneficiaries utilizing at least 1 behavioral health medication (antidepressant, antipsychotic, or anxiolytic/sedative
hypnotic). Similar calculations were completed for each individual drug class, including antidepressants, antipsychotics,
and anxiolytics/sedative hypnotics. Differences in the use of
320 Journal of Managed Care Pharmacy
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behavioral health medications overall and by individual class
were compared between the 2 cohorts by frequencies and
Pearson chi-square testing.
Because part of the PDL initiative focused on excessive
dosing of antipsychotics, we further evaluated differences in
the prescription of antipsychotic medications above the daily
dose requiring PA (according to OVHA) across the 2 study
periods. Utilizing National Drug Codes (NDC), we identified
the strength of the antipsychotic medication dispensed and
calculated the average daily dose using the number of units dispensed and days supply reported in pharmacy claims (average
daily dose = [strength X units] ÷ days supply). We then dichotomized this dose as above or below 125% of the manufacturer’s
maximum daily dose, as specified in OVHA “dosage guidelines
for PA” (aripiprazole ≥ 40 milligrams [mg]; clozapine ≥ 1,125
mg; olanzapine ≥ 50 mg; quietapine ≥ 1,000 mg; risperidone
≥ 10 mg; and ziprasidone ≥ 200 mg)14 and compared this quantity between the 2 cohorts using Pearson chi-square analysis.
To compare costs for behavioral health medications in each
of the cohorts, we analyzed costs paid by the Vermont Medicaid
program (not including manufacturer rebates from federal payments and supplemental rebates) after adjusting for inflation
utilizing methods developed by the Bureau of Labor Statistics.15
All costs were adjusted for inflation according to the December
2007 Consumer Price Index (CPI) for medical costs in the
Boston-Brockton-Nashua area (December, 2007 CPI = 489.8),
which was the closest available geographical area to Vermont.
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FIGURE 2

Selection of Beneficiaries for Post-PA Exemption Cohort

Vermont Medicaid beneficiaries enrolled
January 1, 2007, through December 31, 2007
n = 175,559
Beneficiaries excluded for dual eligibility in
Medicaid and Medicare
n = 34,892 (19.9%)
Beneficiaries enrolled only in Medicaid
n = 140,667
Beneficiaries excluded for enrollment in other
OVHA programs
n = 17,213
Beneficiaries with claims paid only by Medicaid
n = 123,454
Beneficiaries excluded with hemophilia (n = 4)
Beneficiaries excluded with Hunter’s Syndrome (n = 1)
Eligible post-PA exemption cohort
n = 123,449
OVHA = Office of Vermont Health Access; PA = prior authorization.

For each month during the study period, we identified the CPI
for medical care costs in the Boston-Brockton-Nashua Area
(e.g., CPI = 456.7 for June 2006). We then determined the percent inflation by dividing the CPI for December, 2007 by the
CPI for each month during the study period. Costs within each
month were then multiplied by this factor to adjust the costs
for inflation. Within each cohort, we calculated per member
per month (PMPM) costs for all pharmaceuticals (including behavioral health medications), for nonbehavioral health
medications, for behavioral health medications overall, and for
each of the 3 classes of behavioral health medications. We then
compared costs across the 2 cohorts utilizing t-tests.
Behavioral Health Hospitalizations
Finally, as shifts in drug utilization patterns may affect behavioral health hospitalizations, we assessed rates of hospitalization between the 2 cohorts. We identified all hospitalizations
for each study period where a mental health disorder (bipolar
disorder, depression, schizophrenia, personality disorders,
anxiety disorders, and other mental health disorders such as
delusional disorders and pervasive developmental disorders)
was listed as the principal diagnosis on the facility claim (Table
1). Inpatient hospitalizations were identified using a unique
claim type code present in the Vermont Medicaid database.
The claim type code for inpatient claims includes hospitalizations at general hospitals, freestanding psychiatric hospitals,
and state mental health hospitals. We then compared the
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TABLE 1

Hospitalization and Drug Class Codes

Primary
Hospitalization
Diagnosis
Depression
Schizophrenia
Bipolar disorder
Personality disorder
Anxiety disorder
Other mental health
disorders

Drug Classes
Antipsychotics
Antidepressants

ICD-9-CM Codes
296.2, 296.3, 298.0, 300.4, 309.0, 309.1
295.0-295.9
296.0, 296.1, 296.4-296.8
301.xx except 301.21
300.0-300.02, 300.11, 300.21-300.23, 300.3,
300.7, 300.81, 300.82, 309.81
297.0-297.9, 298.2-298.4, 298.9, 299.0-299.9,
300.10, 300.5, 300.6, 300.8, 302.0-302.9, 306.0307.9, 308.0-308.9, 309.22, 309.23, 309.29,
309.82, 309.83, 310.0-310.9, 312.0-316.9
Drug Class Codesa
H2G, H2L, H7O, H7P, H7R, H7S, H7T, H7U, H7X,
H7Z
H2J, H2K, H2S, H2U, H2W, H2X, H7B, H7C,
H7D, H7E, H7J
H2D, H2E, H2F

Anxiolytics/sedative
hypnotics
a First DataBank Specific Therapeutic Class (STC) codes (First DataBank, San
Francisco, CA).
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical
Modification.

proportions of inpatient hospitalizations from each study
period using Pearson chi-square testing.
All statistical tests were performed using an a priori
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TABLE 2

Demographic Characteristics of All Vermont Medicaid Beneficiaries
Eligible for Study Inclusion Stratified by Study Perioda

PA Exemption Cohort
Post-PA Exemption Cohort
Variable
n = 124,169b
n = 123,449c
P Valued
Age
Mean [SD] and t-test P value
20.4  [16.4]
21.2  [17.0]
< 0.001
Age ranges in years
% (n) Pearson chi-square P value
Younger than 18
54.9% (68,095)
53.0% (65,420)
18-34
24.6% (30,597)
24.9% (30,691)
< 0.001
35-64
20.2% (25,058)
21.8% (26,853)
65 or older
0.3%
(381)
0.4%
(448)
Gender
% (n) Pearson chi-square P value
Female
53.8% (66,726)
53.8% (66,341)
0.995
Male
46.2% (57,405)
46.2% (57,071)
Race
% (n) Pearson chi-square P value
Black
1.2%
(1,532)
1.3%
(1,577)
White
55.6% (68,993)
55.4% (68,316)
0.067
Other
0.8%
(997)
0.9%
(1,109)
Not known/not reported
42.4% (52,609)
42.5% (52,410)
a Percentages may not total 100% due to rounding. The PA exemption period was the 12 months between July 1, 2005, and June 30, 2006; the post-PA exemption period
was the 12 months between January 1, 2007, and December 31, 2007.
b38 beneficiaries were missing demographic information in the PA exemption cohort.
c 37 beneficiaries were missing demographic information in the post-PA exemption cohort.
dT-test for the comparison of mean age and Pearson chi-square for the other characteristics.
PA = prior authorization; SD = standard deviation.

TABLE 3

Users of Behavioral Health Medications

PA Exemption
Post-PA Exemption
Cohort a
Cohortb
Absolute
Percent
Pearson
n = 124,169
n = 123,449
Change
Change (%)
Chi-Square
P Value
% utilizing beneficiaries (n)
Antidepressants
14.4% (17,872)
15.4% (18,968)
1.0
6.9
46.16
< 0.001
SSRI
10.2% (12,694)
11.1% (13,697)
0.9
8.8
TCA
1.3% (1,588)
1.3% (1,580)
0.0
0.0
53.09
< 0.001
2.9% (3,590)
3.0% (3,691)
0.1
3.4
Otherc
Antipsychotics
3.6% (4,487)
3.8% (4,724)
0.2
5.6
7.85
0.005
Typical
0.5%
(678)
0.6%
(760)
0.1
20.0
9.51
0.009
Atypical
3.1% (3,809)
3.2% (3,964)
0.1
3.2
Anxiolytics/sedatives
6.4% (7,956)
7.5% (9,240)
1.1
17.2
111.21
< 0.001
Benzodiazepine
5.1% (6,366)
6.0% (7,407)
0.9
17.6
Sleep aid
1.2% (1,462)
1.4% (1,736)
0.2
16.7
121.77
< 0.001
Barbiturate
0.1%
(128)
0.1%
(97)
0.0
0.0
Any behavioral health medicationd
17.8% (22,130)
19.2% (23,717)
1.4
7.9
79.22
< 0.001
aThe PA exemption period was the 12 months between July 1, 2005, and June 30, 2006.
bThe post-PA exemption period was the 12 months between January 1, 2007, and December 31, 2007.
cOther antidepressants include MAOIs, NDRIs, SNRIs, and alpha-2 receptor antagonist antidepressants.
d Beneficiaries in this row were counted once if they had at least 1 pharmacy claim for antidepressants, antipsychotics, or anxiolytics/sedatives.
MAOI = monoamine oxidase inhibitor; NDRI = norepinephrine and dopamine reuptake inhibitor; PA = prior authorization; SNRI = serotonin-norepinephrine reuptake
inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.
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TABLE 4

Beneficiaries Exceeding OVHA Atypical Antipsychotic Daily Dose Limitationsa
PA Exemption Periodb

Post-PA Exemption Periodc

% (n)
% (n)
Pearson
Daily Dose
Sample Size
Exceeding Dose
Sample Size
Exceeding Dose
Chi-Square
P Value
Medication
Requiring PA
4,374
3.1% (134)
4,586
2.2% (101)
6.50
0.011
All atypical antipsychotics combinedd
Aripiprazole
≥ 40 mg
884
5.4% (48)
880
3.4% (30)
4.26
0.039
Clozapine
≥ 1,125 mg
84
8.3% (7)
91
0.0% (0)
7.90
0.005
Olanzapine
≥ 50 mg
385
1.0% (4)
325
1.2% (4)
0.06
0.809
Quetiapine
≥ 1,000 mg
2,291
1.7% (39)
2,330
1.6% (38)
0.04
0.850
Risperidone
≥ 10 mg
1,478
1.7% (25)
1,564
0.8% (13)
4.56
0.033
Ziprasidone
≥ 200 mg
272
8.1% (22)
343
5.8% (20)
1.21
0.270
aThese are not counts of actual PA requests, but counts of patients with daily doses above the PA guideline set by the OVHA.14 Because patients could be on multiple
antipsychotics during each of the 2 study periods, the estimates are shown at the the patient level.
bThe PA exemption period was the 12-month period from July 1, 2005, through June 30, 2006.
cThe post-PA exemption period was the 12-month period from January 1, 2007, through December 31, 2007.
d Because a beneficiary may have received more than 1 atypical antipsychotic at high dose, the total sample size is the count of unique beneficiaries, not the sum of the
beneficiary counts for the individual drugs.
mg = milligrams; OVHA = Office of Vermont Health Access; PA = prior authorization.

2-tailed alpha level of 0.05, and all analyses were performed
using SAS statistical software (Version 9.1.3, SAS Institute
Inc., Cary, NC).
■■ Results
The final study sample in the PA-exemption period (July 1,
2005, through June 30, 2006) was 124,169 (Figure 1). In the
post-PA exemption period from January 1, 2007, through
December 31, 2007, 123,449 beneficiaries met the criteria for
study inclusion (Figure 2). The mean (SD) ages of Medicaid
beneficiaries in this study were 20.4 (16.4) years in the PA
exemption period and 21.2 (17.0) years in the post-PA exemption period (Table 2). The study population was predominantly
younger than 18 years of age (54.9% PA exemption period,
53.0% post-PA exemption period). Therefore, by definition,
more than 50% of the population during the PA exemption
period qualified for the SPMI exemption by age alone. The
majority of beneficiaries were female (53.8% of beneficiaries
were female during both time periods). Race and ethnicity were
also equally distributed in the 2 periods; however, a large portion of beneficiaries were missing race/ethnicity information
during both study periods (> 42%).
The use of any behavioral health medication rose from
17.8% in the PA exemption period to 19.2% in the post-PA
exemption period (P < 0.001), a relative increase of 7.9% (Table
3). Utilization increased for each of the 3 sub-classes of behavioral health medications in the post-PA exemption period compared with the period in which the PA exemption was in effect,
from 3.6% to 3.8% of beneficiaries who received antipsychotics
P = 0.005), from 14.4% to 15.4% of beneficiaries who received
antidepressants (P < 0.001), and from 6.4% to 7.5% of beneficiaries who received anxiolytics/sedative hypnotics (P < 0.001).
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There were 4,374 beneficiaries who received 1 or more
atypical antipsychotics in the PA exemption period versus
4,586 beneficiaries in the post-PA exemption period (Table 4).
The proportion of beneficiaries who received 1 or more highdose atypical antipsychotics that would have required a PA
(for receipt of average daily dosing greater than the maximum
established by OVHA) decreased from 3.1% (n = 134) in the PA
exemption period to 2.2% (n = 101) in the period after discontinuation of the PA exemption (P = 0.011). Among the 6 individual atypical antipsychotics, the proportion of beneficiaries
who should have received a PA for high-dose therapy declined
significantly in the post-PA exemption period for aripiprazole,
clozapine, and risperidone (Table 4).
Overall costs for pharmaceuticals increased from $82.5
million in the 12-month period from July 1, 2005, through
June 30, 2006, to $90.1 million in the 12-month period from
January 1, 2007, through December 31, 2007, or 9.9% from
$55.34 to $60.82 PMPM (Table 5). The costs for 3 classes of
behavioral health medications increased by only 2.1% in the
post-PA exemption period compared with the PA exemption
period (from $12.76 to $13.03 PMPM), and therefore accounted
for a smaller proportion of total pharmacy spending in the
post-PA exemption period (21.4%) compared with the PA
exemption period (23.1%).
The 9.9% increase in PMPM spending for all drugs and
the 2.1% increase in PMPM spending for the 3 classes of
behavioral health drugs were attributable to lower costs per
pharmacy claim while utilization of behavioral health medications increased minimally. For all pharmaceuticals, the average cost per claim declined by 4.0% from $71.04 to $68.21
(Table 5). For the 3 classes of behavioral health drugs, the
average cost per claim declined by 12.9%, from $94.05 to
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TABLE 5

Utilization and CPI-Adjusted Medication Costs
PA Exemption Cohort a
n = 124,169
Totale

PMPM

Post-PA Exemption Cohortb
n = 123,449
Totale
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Total

PMPM

Percent
Change
(%)c

T-test
Statisticd

P Value
All medications
Claims
1,160,889
0.78
1,320,875
0.89
159,986
0.11
14.1
Cost
$82,469,957
$55.34
$90,093,724
$60.82
$7,623,767
$5.48
9.9
413.75
< 0.001
Cost per claim
$71.04
$68.21
$2.83
-4.0
All nonbehavioral health medications
Claims
958,666
0.64
1,085,334
0.73
126,668
0.09
14.1
Cost
$63,450,118
$42.58
$70,797,124
$47.79
$7,347,006
$5.21
12.2
396.97
< 0.001
Cost per claim
$66.19
$65.23
$0.96
-1.5
All behavioral health medicationsf
Claims
202,223
0.14
235,541
0.16
33,318
0.02
14.3
Cost
$19,019,839
$12.76
$19,296,601
$13.03
$276,762
$0.27
2.1
307.44
< 0.001
Cost per claim
$94.05
$81.92
$12.13
-12.9
Antidepressants
Claims
121,737
0.08
138,837
0.09
17,100
0.01
12.5
Cost
$7,984,246
$5.36
$6,848,253
$4.62
$1,135,993
$0.74
-13.8
341.84
< 0.001
Cost per claim
$65.59
$49.33
$16.26
-24.8
Antipsychotics
Claims
41,972
0.03
48,371
0.03
6,399
0.00
0.0
Cost
$9,886,726
$6.64
$10,936,675
$7.38
$1,049,949
$0.74
11.1
215.21
< 0.001
Cost per claim
$235.56
$226.10
$9.46
-4.0
Anxiolytics/sedative hypnotics
Claims
38,514
0.03
48,333
0.03
9,819
0.00
0.0
Cost
$1,148,867
$0.77
$1,511,673
$1.02
$362,806
$0.25
32.5
134.02
< 0.001
Cost per claim
$29.83
$31.28
$1.45
4.9
aThe PA exemption period was the 12 months between July 1, 2005, and June 30, 2006.
bThe post-PA exemption period was the 12 months between January 1, 2007, and December 31, 2007.
cFor the “claims” and “costs” rows, represents the percentage change in the PMPM value. For the “cost per claim” rows, represents the percentage change in the cost per
claim.
dComparing the average PMPM cost in the 2 study cohorts.
e All costs were adjusted for inflation according to the December 2007 CPI for medical costs in the Boston-Brockton-Nashua area (489.80), which was the closest available
geographical area to Vermont. Costs from all months (except December 2007) were inflated to more appropriately compare costs during a period of high inflation for medical costs. Claims are pharmacy claims.
fBehavioral health medications defined as antidepressants, antipsychotics, and anxiolytics/sedative hypnotics.
CPI = Consumer Price Index; PA = prior authorization; PMPM = per member per month.

$81.92. The antidepressants accounted for most of the drop
in the average cost per claim for the behavioral health drugs,
declining by 24.8% from $65.59 to $49.33; the average cost per
claim for the antipsychotics declined by 4.0% from $235.56 to
$226.10; while the average cost per claim for the anxiolytics/
sedative hypnotics increased by 4.9% from $29.83 to $31.28.
The cost per claim for all nonbehavioral health drugs declined
by 1.5% from $66.19 to $65.23.
The decline in the average cost per pharmacy claim helped
suppress the effects of increased utilization in the post-PA
exemption period for all drugs including the behavioral health
drugs. Spending declined by 13.8% for antidepressants in the
post-PA exemption period (from $5.36 to $4.62 PMPM), but
increased by 11.1% for antipsychotics (from $6.64 to $7.38
PMPM) and by 32.5% for the anxiolytics/sedative hypnotics
(from $0.77 to $1.02 PMPM). Utilization of the 3 behavioral

PMPM

Absolute Change

health classes of drugs was relatively stable at 0.14 claims
PMPM in the PA exemption period and 0.16 claims PMPM in
the post-PA exemption period, including essentially no change
in the antidepressants, from 0.08 claims PMPM to 0.09 claims
PMPM, and no change in the antipsychotics and the anxiolytics/sedative hypnotics, both 0.03 claims PMPM in both study
periods (Table 5).
Regardless of study period, antipsychotics accounted for the
largest proportion of spending on the 3 classes of behavioral
medications, followed by antidepressants. In the PA exemption
period, antipsychotics accounted for 12.0% of total pharmacy
costs ($9,866,726 of $82,469,957) and antidepressants for
9.7% of total pharmacy costs ($7,984,246 of $82,469,957).
A similar percentage of overall pharmaceutical expenditures were accounted for by these medication classes in the
post-PA exemption period. After the PA exemption phase-
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TABLE 6

Incidence of Mental Health Inpatient Hospitalization by Subtype Stratified by Study Period
PA Exemption Cohort a
n = 124,169

Post-PA Exemption Cohortb
n = 123,449

Percent of
Percent of
Beneficiaries
Beneficiaries
Total Number of
with at Least 1
Total Number of
with at Least 1
Absolute
Hospitalizations Hospitalization (n) Hospitalizations Hospitalization (n) Changec
1,099
0.64% (799)
608
0.37% (461)
0.27

Percent
Change
(%)c
-42.2

Pearson
ChiSquarec
89.17

P Valuec
<0.001

Any mental health
hospitalizationd
Depression
459
0.29% (359)
221
0.15% (181)
0.14
-48.3
57.77
<0.001
Schizophrenia
99
0.05% (65)
60
0.04% (44)
0.01
-20.0
3.93
0.048
Bipolar disorder
155
0.11% (137)
95
0.06% (78)
0.05
-45.5
15.86
<0.001
Personality disorder
23
0.01% (18)
20
0.01% (15)
0.00
0.0
0.26
0.613
Anxiety disorder
151
0.10% (120)
98
0.07% (81)
0.03
-30.0
7.35
0.007
212
0.15% (185)
114
0.08% (99)
0.07
-46.7
25.57
<0.001
Other disorders e
aThe PA-exemption period was the 12 months between July 1, 2005, and June 30, 2006.
bThe post-PA exemption period was the 12 months between January 1, 2007, and December 31, 2007.
cCalculated by comparing the percentage of beneficiaries with at least 1 hospitalization in each study period.
dTotal number of beneficiaries who had at least 1 mental health hospitalization for depression, schizophrenia, bipolar disorder, personality disorder, anxiety disorder, or
other disorder.
eOther mental health disorders are specified by the ICD-9-CM codes in Table 1.
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; PA = prior authorization.

out, the cost of antipsychotics increased by approximately
$1,050,000, and the cost of anxiolytics/sedatives increased in
this time period by approximately $363,000. However, during this time period, the cost of antidepressants decreased by
approximately $1,136,000. Spending on all medications other
than behavioral health medications rose by approximately
$7.35 million, and total pharmaceutical spending rose by
approximately $7.62 million (9.2%) in the post-PA exemption
period compared with the PA exemption period.
Results of the analyses of inpatient hospitalizations attributable to behavioral health disorders are presented in Table
6. Overall, during the PA-exemption period, there were 491
(44.7%) fewer mental health inpatient hospitalizations in the
post-PA exemption period (n = 608) compared with the PA
exemption period (n = 1,099). The unique count of beneficiaries
with any mental health hospitalization (at least 1 hospitalization for depression, schizophrenia, bipolar disorder, personality disorder, or other mental health disorders) decreased from
0.64% (n = 799) to 0.37% (n = 461; P < 0.001). The rates of
hospitalization for 5 of the 6 specific mental health diagnostic
categories were significantly lower in the period after removal
of the PA exemption compared with the period of the PA
exemption (Table 6).
■■ Discussion
We conducted a retrospective cohort study to quantify the
effect of a managed care initiative to promote the costeffective utilization of behavioral health medications and
services. Rather than directly evaluating the effect of program
implementation, we focused on the phase-out of an exemption
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that allowed certain beneficiaries with “severe and persistent
mental illness” to be exempt from the initiative. All covered
beneficiaries in the state of Vermont were subject to the use
of a PDL after the SPMI exemption was phased out in June
2006, and thus if the implementation of the PDL was effective,
changes in utilization and costs should be evident following the phase-out of the exemption. Our study is important
because evaluation of public programs is imperative to ensure
that health care initiatives maintain quality while being costeffective and use available resources efficiently.
Since a large portion of the population qualified for
exemption from the implementation of the PDL, it is not surprising that costs for behavioral health medications continued
to escalate after implementation of the PDL. However, our
analysis shows only a modest 2% increase in PMPM costs for
behavioral health medications, while PMPM costs increased
12% for all other pharmaceuticals following the phase-out of
the PA exemption. This suggests that the implementation of
a PDL with a corresponding PA process may be an effective
tool for managing cost increases without adversely affecting
utilization of target drugs in a publicly funded pharmaceutical
assistance program. Equally important was the relatively stable
utilization of behavioral health medications between the 2 time
periods, indicating that the implementation of the PDL may be
shifting prescribing towards more cost-effective medications
while not deterring medication prescribing as warranted for
mental health conditions.
Our analyses also indicated that hospitalizations and
high-dose prescriptions of antipsychotic medications did not
increase in the period after elimination of the PA exemption for
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mental health drugs. Hospitalizations decreased by almost onehalf in the year after elimination of the exemption (2007). More
research may help determine if treatment was shifted to other
areas, such as outpatient clinics, and to our knowledge there
were no other initiatives by OVHA targeting mental health
inpatient hospitalizations. Research by Shern et al. (2008) suggested that mental health costs shifted from health care centers
to private care through family and friends after the introduction of Medicaid managed care.16 In that study, although costs
to the Florida Medicaid system did decrease in the presence of
managed care, there were no differences in societal costs. It is
plausible that the decrease in inpatient hospitalizations seen
in this study resulted in subsequent increases in care in other
health care sectors.
Kaskie et al. (2006) compared 2 capitated models of
Medicaid mental health service delivery with traditional feefor-service Medicaid among enrollees aged 65 years or older
in Colorado.17 Although our study population differed by the
exclusion of Medicare-eligible enrollees, Kaskie et al. also
found that the introduction of behavioral health managed care
to a Medicaid population reduced expenditures while having
mixed results on rates of utilization. Authors of several studies
have noted that introduction of behavioral health managed care
was associated with reduced utilization of inpatient care.18-20
However, Burns et al. (1999) noted that utilization of intensive
outpatient services increased, while Cook et al. (2004) did not
observe any change in outpatient service utilization.18,20 A multisite study by Leff et al. (2005) concluded that enrolling highuse Medicaid beneficiaries in behavioral health managed care
programs (e.g., behavioral health “carve-outs”) did not seem to
pose any short-term, large-scale negative consequences, such
as an increase in the utilization of intensive inpatient mental
health services.21
Research by Soumerai et al. indicated that managed care
restrictions could have a negative impact on Medicaid subpopulations.22-26 A much-referenced study by Soumerai et al.
(1994) found reductions in the use of behavioral health medications and increased use of mental health services following
the implementation of a 3-prescription monthly payment
limit on psychotropic drugs and acute mental health care in
noninstitutionalized beneficiaries with acute schizophrenia.23
A more recent (2008) analysis concluded that the initiation of
PA for nonpreferred antipsychotics in West Virginia and Texas
decreased the market share of these agents by 13.9% and 2.6%
respectively after 2 years but was not associated with significant reduction in pharmacy reimbursements in either state.24
The authors noted that the economic value of supplemental
rebates associated with the PDL and not reported in available
pharmacy claims could not be evaluated.
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Limitations
Foremost among the limitations of this study, we did not
include a comparison group from another state, but rather
used a pre and post design. As a result, we cannot differentiate the effect of extraneous changes in the marketplace from
the effect of rescission of the PA exemption for SPMI. However,
apparent differences between the population covered in the
state of Vermont’s Medicaid program and other state Medicaid
programs would make selection of a valid comparison group
problematic even if one were available.
Second, our study is a real-world analysis of a managed care
policy change, and we do not know the proportion of the study
cohorts that was affected by the PA exemption. We do know
that the proportion affected by the exemption was greater than
50% of the cohort samples by age alone.
Third, our analyses were restricted to the costs paid to
pharmacies by the OVHA as recorded in pharmacy claims
databases. We were unable to account for manufacturer rebates
that have been negotiated by OVHA, and thus the true costs
to the Medicaid program may be overstated. In addition to
federal rebates, Vermont participates in a multistate pool for
supplemental rebates with Michigan, Alaska, Nevada, New
Hampshire, Hawaii, and Minnesota.12 Drug manufacturer
rebates are significant in Medicaid pharmacy programs,27 but
we have no reason to believe that rebate revenues as a proportion of total spending for mental health drugs would have differed between the 2 time periods in the present study. Although
not broken out by drug class, the state of Vermont reported that
federal rebates were about 27.1% of total pharmacy spending in
the state’s fiscal year 2008, plus an additional 4.7% in supplemental rebates.28
Fourth, we are unable to ascertain the effect of “grandfathering” on costs and utilization. Prior to rescission of the PA
exemption, behavioral health medication users were grandfathered to prevent “destabilization.”14 New users and beneficiaries who had lapses in treatment greater than 4 months became
subject to the PDL upon implementation of the rescission.14
Our study was designed to mitigate the effects of grandfathered users of behavioral health medications by employing
a 6-month “wash-out” period. Published data indicate that
Vermont Medicaid PAs for nonpreferred behavioral health
medications decreased by approximately 54% from January
2006 to November 2007.14 This decrease may have resulted
from greater adherence to the PDL, although an analysis of this
association is beyond the scope of the present study.
Fifth, because we did not have a comparison group from
another state, we could not ascertain the effects of increased
awareness and attention to the relationship between antipsychotic use and a higher prevalence of other disorders
such as metabolic syndrome.29-31 This syndrome is often
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characterized by obesity, hypertension, dyslipidemia, hyperuricemia, and diabetes,29 and people with this constellation
of risk factors have a higher risk for cardiovascular and/or
all-cause mortality.31 Therefore, patients taking antipsychotic
medications might have higher overall drug costs than the
rest of the Medicaid population due to this association. In fact,
a cross-sectional observational study of adult Medicaid beneficiaries found that the presence of any psychiatric diagnosis
significantly increased total health care costs by over 200%
($3,121 per year to $6,995 per year).32 Heightened awareness of
the metabolic syndrome may have led to a reduction in the use
of these medications independent of the phase-out of the SPMI
exemption. Recent research has added further confirmation of
this association.32
Sixth, we did not explore the reasons for the reduction in
average drug cost per pharmacy claim for the 3 mental health
drug classes combined, and for the antidepressants in particular, in the period after elimination of the PA exemption. One
obvious reason is greater adherence to the PDL including the
use of more first-line therapy including generic antidepressants such as citalopram, paroxetine, and sertraline (which first
became available by generic name in June 2006).
■■ Conclusion
Many states such as Vermont have introduced managed care
initiatives in their publicly funded health care programs in
an attempt to maintain quality and restrain cost increases.
The exemption of behavioral health medications from PA for
Medicaid beneficiaries with SPMI was implemented in Vermont
in response to criticism about the possible adverse effects on
a “vulnerable” population. Phase-out of the PA exemption was
completed in June 2006, but current users of behavioral health
medications continued to be “grandfathered” until a lapse in
drug therapy of 4 months or longer occurred. Therefore, the
phase-out of the PA exemption provided an opportunity to
analyze the effect of behavioral health managed care in this
Medicaid population. The growth of PMPM cost for behavioral health medications, which represented 21%-23% of total
pharmaceutical costs, was small compared with the increase in
PMPM costs for nonbehavioral health medications. Secondary
analyses of 2 quality measures, the percentage of beneficiaries
who were hospitalized with mental health diagnoses and highdose prescribing of antipsychotics, declined after removal of
the PA exemption. Despite the PA requirement, utilization of
behavioral health medications PMPM remained stable, and
there was a decrease in the average prescription cost for the
behavioral health medications, particularly antidepressants.
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